An 8-Week Refractory Chronic Cough Study (MK-7264-021)
NCT02612623
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Refractory Chronic Cough
Interventions
DRUG:
Gefapixant
DRUG:
Placebo (for gefapixant)
Sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)